Chief Medical Officer & Senior Vice President of Oncology, Flatiron Health
Before joining Flatiron, Amy was Professor of Medicine at Duke University School of Medicine, and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. For more than a decade, she has pioneered the development of technology platforms to spur novel advancements in cancer care, including the development of systems by which big data can support personalized medicine and scientific discovery. Joining Flatiron was the obvious next step.
Amy went to the University of Pennsylvania as an undergraduate, and then medical school at Duke, where she also did her Internal Medicine residency, a year as Chief Resident, and her hematology/oncology fellowship. She has her PhD from Flinders University in Australia, focused on evidence-based medicine. As an oncologist and palliative care physician, she sincerely believes in putting the patient in the center of the health care story and ensuring that the solutions we build have patient best interests at heart. She is also a mother of two and an avid traveler.
With over 375 publications, Amy is an internationally recognized expert in health services research, comparative effectiveness research, patient reported outcomes, clinical informatics and patient-centered care. She maintains her role at Duke 20 percent, and is an appointee to the Institute of Medicine’s National Cancer Policy Forum, Immediate Past President of the American Academy of Hospice & Palliative Medicine, Secretary of the Board of Directors for the Personalized Medicine Coalition, and leader within several federally-funded research networks. She serves on the Advisory Committee of the Turning the Tide Against Cancer policy initiative. She also serves on the Board of Directors for athenahealth.
Edward Abrahams, Ph.D., is president of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalized medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to more than 225 today.
Previously Dr. Abrahams was executive director of the Pennsylvania Biotechnology Association, where he spearheaded the successful effort that led to the Commonwealth of Pennsylvania’s investment of $200 million to commercialize biotechnology in the state. Earlier he had been Assistant Vice President for Federal Relations at the University of Pennsylvania and held a senior administrative position at Brown University.
Dr. Abrahams worked for seven years for the U.S. Congress, including as a legislative assistant to Senator Lloyd Bentsen, an economist for the Joint Economic Committee under the chairmanship of Representative Lee Hamilton, and as a AAAS Congressional Fellow for Representative Edward J. Markey.
The author of numerous essays, Dr. Abrahams serves on the editorial board of Personalized Medicine and has also taught history and public policy at Brown University and the University of Pennsylvania.
Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb Company
Dr. Averbuch is Vice President, Development, Oncology & Pharmacodiagnostics, Bristol-Myers Squibb. In this role, Dr. Averbuch is responsible for the execution of external clinical collaborations for the company’s immuno-oncology pipeline. Dr. Averbuch also leads the Pharmacodiagnostics Center of Excellence, whose mission is to drive biomarker strategy, optimize biomarker knowledge and tools across all of R&D and execute on the integrated co-development and co-commercialization of diagnostic tests as companions to Bristol-Myers Squibb medicines.
Dr. Averbuch joined Bristol-Myers Squibb in 2006. Prior to his current role, he co-led the Oncology early strategy team, and he was the executive sponsor for Oncology Transition Teams for the execution of Phase 2 Oncology programs. He has made significant Global Clinical Research contributions to business development, and he has participated in multiple successful licensing and acquisition deals.
Dr. Averbuch previously held positions at Merck Research Laboratories, AstraZeneca and Mount Sinai School of Medicine. He received his M.D. and Internal Medicine training from the University of Illinois, Chicago and his Medical Oncology training at the National Cancer Institute in Bethesda, Maryland.
Dr. Averbuch has authored over 60 peer reviewed publications and book chapters, and he is a co-author on one patent. He is currently on the Personalized Medicine Coalition Board of Directors, the Steering Committee of the National Biomarker Development Alliance, the Advisory Board for the University of Kansas Institute for Advancing Medical Innovation, and he is a member of the American Society of Clinical Oncology and the American Association for Cancer Research having served on multiple committees for both organizations. Dr. Averbuch is the 2014 recipient of the University of Illinois College of Medicine Distinguished Alumnus Award.
Mr. de Crescenzo was appointed President and Chief Executive Officer of Emdeon in September 2013. Prior to that, Mr. de Crescenzo was Senior Vice President and General Manager of Oracle's Global Health Sciences business. Previously, he spent 10 years at IBM Corporation, including his last role as Senior Executive for Global Healthcare Business Consulting Services. Earlier in his career, he held leadership positions in a major hospital system, a large physician practice, and at a major health insurer. Mr. de Crescenzo began his career in investment banking, working with US and European clients in the areas of corporate finance and mergers and acquisitions.
Mr. de Crescenzo earned a B.A. in Political Science from Yale University and an M.B.A. from Northeastern University.
President & CEO, Global Liver Institute
Donna R. Cryer, J.D., has channeled her personal experience as an IBD and liver transplant patient into professional advocacy as president and chief executive officer of the Global Liver Institute, the innovation and collaboration platform for the liver community. Ms. Cryer most recently served as chair, president & chief executive officer of the American Liver Foundation, the largest and oldest national nonprofit organization serving liver disease patients and their families. She was the first patient to lead the organization in its 36-year history.
For eight years, Ms. Cryer has led CryerHealth, a health care consulting firm providing strategic counsel to top biopharmaceutical companies, patient advocacy organizations, and emerging technology firms on patient engagement in health information technology, drug discovery, and clinical decision making.
Her e-health experience includes participating in the launch of the Office of National Coordinator for HIT (ONC) consumer engagement campaign and serving on the ONC technical expert panel on patient-generated health data, participating as a member of the White House e-health equity taskforce and the judging panel on the White House design challenge on innovating the electronic patient medical record. Her blog, DCpatient – An Impatient Patient’s Perspective from Washington, DC, and twitter feed @DCpatient are listed as top resources for insights into emerging e-patients and patient advocates.
Ms. Cryer is a patient representative to the U.S. Food and Drug Administration, a merit reviewer for the Patient Centered Outcomes Research Institute (PCORI), and a member of the Stakeholder Advisory Group to the NIH Learning Health System Research Collaboratory. Additionally, Ms. Cryer serves on the Gastroenterology Board of the American Board of Internal Medicine, the American Society of Clinical Oncology Guidelines Committee; Hepatitis B Infection Screening in Patients Receiving Chemotherapy for Treatment of Malignant Diseases, the Board of the Personalized Medicine Coalition, is a member of the Patient and Consumer Advisory Council for the Center for Medical Technology Policy, and is an adviser to HarborPath, a patient assistance program for those living with HIV/AIDS and HCV.
Ms. Cryer received an undergraduate degree from Harvard/Radcliffe Colleges and received a Juris Doctorate from the Georgetown University Law Center.
She resides in Washington, DC, with her husband, Dennis R. Cryer, MD, FAHA.
CEO, M2Gen; Director, DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center
Dr. William (Bill) S. Dalton is Founder and CEO of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
Vice President, Oncology Medical Sciences, Astellas Pharma Global Development
Dr. Eck is Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma Global Development (Headquartered in Northbrook, IL). He is directly responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalized cancer therapies. Dr. Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company (2007-2011) where he was responsible for the clinical pharmacology components of drug development including both early phase clinical studies and late stage drug development studies. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. Prior to Joining Lilly, Dr. Eck served in a variety of drug development leadership roles at Pfizer, Inc (2002-2007).
Dr. Eck is a board certified Hematologist/Oncologist with broad drug development experience in Oncology and Neuroscience. He is a Fellow of the American Association for the Advancement of Science (Pharmaceutical Sciences). He serves on the Scientific Advisory Board of the ACGT Foundation (which supports academic cancer research), and is a member of the Executive Committee of the Fairbanks Institute (an institution dedicated to developing data banks to enable personalized medicine). He also serves on the Advisory Board of the Keck Graduate School (Claremont, CA).
Senior Vice President and Chief Medical Officer, Development Center of Excellence, Eli Lilly & Company
Timothy Garnett, FRCOG, MFFP, FFPM, is Chief Medical Officer, Senior Vice President and Co-Leader of the Development Center of Excellence managing Medical Affairs, Global Health Outcomes, Regulatory, Safety and Translational Medicine/Pharmacogenomics for Eli Lilly and Company. During his 14 years at Lilly, Dr. Garnett has served as Vice President for Global Patient Safety; Global Brand Development Leader and Group Medical Director responsible for the development of Duloxetine for incontinence, pain and depression; Medical Director-Duloxetine SUI Team; and European Clinical Research Physician for EVISTA.
Prior to joining Lilly, Dr. Garnett had acquired 7 years of experience, holding a variety of positions in the pharmaceutical industry in Europe with Organon Laboratories.
He qualified in Medicine at St. George's Hospital in London. Dr. Garnett is a Fellow of the Royal College of Obstetricians and Gynecologists in the United Kingdom. He is also an active board member of the following: Centre for Innovation in Regulatory Science; Indiana Health Industry Forum; and Eiteljorg Museum of American Indians and Western Art.
Board of Trustees Member, American Medical Association
Julie K. Goonewardene is a recognized leader in technology commercialization, business formation, and public/private partnerships. Based on her successes in these areas, Ms. Goonewardene was recently elected to the Board of Trustees for the American Medical Association (AMA).
In addition to serving in her current role as Associate Vice Chancellor for Innovation and Entrepreneurship at the University of Kansas (KU), she is president of KU Innovation & Collaboration and a professor of practice in the KU School of Business. Ms. Goonewardene is responsible for all university-wide commercialization efforts with the intellectual property, company formation, corporate outreach and foundation research relationship groups reporting to her.
Prior to KU, she held various roles at Purdue University. One of her primary focus areas was company formation and capital acquisition for start-up companies. While at Purdue she designed and managed Purdue’s first venture fund. Ms. Goonewardene is an experienced entrepreneur herself, having co-founded and served as president and CEO of Cantilever Technologies, a venture-backed software company that was successfully acquired in 2004.
Ms. Goonewardene earned a B.S. degree with Honors in Management and a master’s degree in Health Communication from Purdue University and is currently a member of The Economic Club of Chicago and The Chicago Finance Exchange.
National Medical Director, Oncology Solutions, Aetna
Michael Kolodziej M.D. is the National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna. Dr. Kolodziej attended college and medical school at Washington University in St. Louis. He completed internal medicine and hematology-oncology training at the University of Pennsylvania in Philadelphia.
After completing training, Dr. Kolodziej joined the faculty at the University Of Oklahoma School Of Medicine where he was an associate professor.
He joined New York Oncology in the winter of 1998, and was a partner in the practice until December 2012. He was an active member of the US Oncology Pharmacy and Therapeutics committee, on the executive committee from 2002-2011, and chairman from 2004-2011. He served as Medical Director for Oncology Services for US Oncology from 2007-2011.In this role, he helped direct the implementation of the USON clinical pathways initiative, the integration of the USON EMR into this program, and the development of the USON disease management and advanced care planning programs, now known as Innovent Oncology.
He has published several manuscripts and given several presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost of care in oncology. Dr. Kolodziej is married to Dr. Regina Resta, also a medical oncologist with New York Oncology Hematology, and they have two children, Peter (19) and Katherine (16).
Medical Director, Moffitt Cancer Center DeBartolo Family Personalized Medicine Institute
Dr. Howard McLeod is the Medical Director of the DeBartolo Family Personalized Medicine Institute at the Moffitt Cancer Center. He is also a Senior Member of the Division of Population Sciences. Most recently, he was the Fred Eshelman Distinguished Professor and Founding Director of the UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill. Dr. McLeod held appointments in the UNC Schools of Pharmacy and Medicine, the Carolina Center for Genome Sciences, and the Lineberger Comprehensive Cancer Center.
Dr. McLeod is also chair of the
NHGRI eMERGE network external scientific panel and a recent member of the FDA
committee on Clinical Pharmacology and the NIH NHGRI Advisory Council. Since 2002, Dr McLeod has been vice chair for
Pharmacogenomics for the NCI clinical trials cooperative group CALGB/ALLIANCE,
overseeing the largest oncology pharmacogenomics portfolio in the world. Dr. McLeod is also a 1000 talent scholar of
China and a professor at Central South University in Changsha, China. He directs the Pharmacogenetics for Every
Nation Initiative, which aims to help developing countries use genetic
information to improve National Drug Formulary decisions.
Dr. McLeod has also been an active entrepreneur, serving
on the Board of Directors, Scientific Advisory Board, and as a domain expert
consultant to for-profit companies. He
has founded both for-profit and non-profit companies in the USA and China. Howard has published more than 475 peer reviewed
papers on pharmacogenomics, applied therapeutics or clinical pharmacology and
continues to work to integrate genetics principles into clinical practice to
advance individualized medicine.
Senior Vice President, Government Affairs, Endo Pharmaceuticals
Brian Munroe is the founder and the immediate Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of the PMC Public Policy Committee and on the Executive Committee of the PMC Board of Directors.
Brian is a twenty year veteran of health care public policy, advocacy, and communications. His areas of expertise are in FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently the Vice-President in charge of Washington office, the Public Policy group, State Government Relations and, the Political Action Committee at Endo. He also serves on Endo’s Executive Operations Committee.
Brian’s breadth in health care policy stretches across pharma/biotech, home health care, diagnostics, medical devices, clinical laboratories, and health care payors. His geographical responsibilities have included the fifty states, the Federal government and Congress, and for a short time the European Union and member countries.
Brian began his career in Washington, D.C. working for United States Senator Alan Cranston (D-CA).
Brian currently lives in the Washington, D.C. area with his wife Vicky and their four children.
Director, Helomics Corporation
D. Stafford O'Kelly, retired, was formerly President of Abbott Molecular. He served in this role from 2007-2012.
Mr. O'Kelly joined Abbott in 1984 and served in various management positions. These included Vice President, Latin America/Canada Operations; Division Vice President Finance, Abbott International, Division; Vice President and Controller, Ross Products Division (now Abbott Nutrition); and Vice President, Finance, TAP Pharmaceuticals, Inc.
Mr. O'Kelly serves on the boards of Youth Conservation Corps, Inc., and the Clara Abbott Foundation.
He has a bachelor's degree in engineering and MBA from Trinity College in Dublin, Ireland.
President & CEO, Foundation Medicine
Dr. Pellini joined Foundation Medicine as President and Chief Executive Officer in May 2011, bringing a breadth of experience in life sciences and the clinical diagnostics and laboratory industries to the company. Dr. Pellini came to Foundation Medicine from Clarient, a GE Healthcare Company, where he held the position of President and Chief Operating Officer. Dr. Pellini joined GE Healthcare through the integration of Clarient, Inc., where he worked with the company’s leadership team to drive operational excellence and reimbursement strategies in parallel with the development and commercialization of multiple diagnostic tests. Dr. Pellini’s leadership was instrumental in building Clarient to the highly successful acquisition by GE Healthcare in October 2010.
Prior to his tenure with Clarient, Dr. Pellini served as Vice President, Life Sciences at Safeguard Scientifics, Inc. where he leveraged his business and medical expertise to explore new market opportunities and to support Safeguard’s partner companies. Prior to Safeguard, he was Executive Vice President and Chief Operating Officer at Lakewood Pathology Associates, a national molecular pathology services company, which was acquired by Water Street Healthcare Partners in 2006. Previously, Dr. Pellini was an Entrepreneur-in-Residence at BioAdvance, where he was responsible for identifying early-stage life science opportunities. He also served as President and Chief Executive Officer of Genomics Collaborative, Inc., a Boston-based biotech firm that was acquired by SeraCare Life Sciences, Inc. in 2004.
Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College of Thomas Jefferson University. He is a board member of the Personalized Medicine Coalition and serves on the President’s Leadership Council of Jefferson Medical College.
Chairman of the Board, Chief Executive Officer & President, Genomic Health
Committed to changing the paradigm of cancer care, Kim Popovits has led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon and prostate cancers that address the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today.
Kim has served as Genomic Health’s Chairman of the Board since 2012, and Chief Executive Officer and President since 2009. She was President and Chief Operating Officer since joining the company in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales at the biotechnology company, Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation. Kim currently serves on the boards of the California Life Sciences Association (CLSA), the Personalized Medicine Coalition (PMC), the American Clinical Laboratory Association (ACLA), and ZS Pharma. Kim is also the President of The Coalition for 21st Century Medicine, and serves as an Adviser to the Healthcare Businesswomen’s Association (HBA).
Kim’s contributions to science and the commercialization of the biotechnology industry have been acknowledged by multiple organizations including being named Most Admired CEO in 2014 as well as one of the Most Influential Women in the Bay Area from 2006-2012 by the San Francisco Business Times. She was also named Woman of the Year in 2008 by the Women Health Care Executives.
Kim holds a Bachelor of Arts degree in Business from Michigan State University.
Vice President for Policy & Research, PhRMA
Lori Reilly is Vice President for Policy & Research at the Pharmaceutical Research and Manufacturers of America (PhRMA). Ms. Reilly oversees PhRMA’s development of legislative and policy analysis and research studies on health care issues including pharmaceutical economics and utilization, health care quality, direct-to-consumer (DTC) advertising/marketing and promotion, import safety, comparative effectiveness and intellectual property.
In addition to her public policy work, Ms. Reilly is a frequent presenter on industry-related issues and is an industry spokesperson, appearing regularly on CNN, Fox News, ABC News, MSNBC and a host of other media outlets. Ms. Reilly testified before the House Energy and Commerce Subcommittee on Health to discuss the importance of reauthorization of the pediatric exclusivity program and the Food and Drug Administration Globalization Act.
Prior to joining PhRMA, she was counsel at the U.S. House of Representatives Committee on Commerce. And before joining the House Commerce Committee, Ms. Reilly was Chief of Staff to Rep. Jon Christensen.
Ms. Reilly received a B.A. in Political Science from the University of Nebraska-Lincoln (1993), where she graduated with Honors, and a J.D. from the University of Nebraska College of Law (1996). She is a Member of the Virginia Bar.
Executive Director and Head of Diagnostics, Pfizer Inc.
Hakan leads Pfizer’s Companion
Diagnostics efforts across the Worldwide R&D organization and is also
responsible for Pfizer’s internal Biobank group. His formal education includes BS
(1983) and MS (1984) degrees from Ankara University in Turkey, PhD (1990) in
Quantitative Genetics from the University of Minnesota as a Rotary Foundation
Scholar, and postdoctoral studies in genetics at the University of
in the biotech industry in human genetics and statistical genetics fields
across multiple disease areas before moving to Parke-Davis Pharmaceuticals in
1998 to direct human genetics, statistical genetics and pharmacogenetics
programs. Following the merger of
Warner-Lambert/Parke-Davis with Pfizer, he has held positions of increasing responsibility
in Clinical Pharmacogenomics, Molecular Profiling, and Translational
Oncology. Hakan interacted closely with
Pfizer’s Executive Leadership Team and the Board of Directors to define and
implement Pfizer’s current companion diagnostics strategy. One of his most significant professional
accomplishments was to lead the companion diagnostics program for Xalkori®
(Crizotinib), Pfizer’s flagship program in companion diagnostics. Hakan served on the clinical development and
drug/diagnostics submission teams and led the companion diagnostics program to
a successful delivery, resulting in simultaneous FDA approvals of both the drug
and the companion diagnostic test in 2011.
Hakan was then promoted to his current role to provide companion
diagnostics leadership across Pfizer’s pharmaceutical pipeline. He led the internal efforts that resulted in
companion diagnostics partnerships with Dako/Agilent and Siemens Healthcare
Diagnostics, among others. Hakan’s
contributions to precision medicine and companion diagnostics have been widely
recognized through both internal and external awards, frequent speaking
engagements, and press coverage. He is
the author of over 30 referred scientific articles as well as many other
papers, abstracts and book chapters.
Hakan is keenly interested in technologies for identification of patient sub-groups for targeted treatments and development of companion diagnostics to advance Precision Medicine for the improvement of individualized healthcare. He is an active member of civic clubs, and enjoys cycling, soccer, and stand-up paddle-boarding.
Chief Medical Officer, Leica Biosystems
Jared N. Schwartz, M.D., Ph.D., F.C.A.P., brings 30 years of pathology expertise to his role as Chief Medical Officer at Leica Biosystems. Formerly with Aperio, and previously serving as President of the College of American Pathologists, and Director of Pathology and Laboratory Medicine at Presbyterian Healthcare in Charlotte, North Carolina.
Board certified in anatomic and clinical pathology with subspecialty boards in medical microbiology and cytopathology, he is a graduate of Duke University Medical School, where he completed his residency and fellowship training, and served as chief resident. He was appointed to the Clinical Laboratory Improvement Advisory Committee by HHS, and was a co-chair and author of the ASCO/CAP Guidelines on HER2, which was published in the January 2007 editions of the Journal of Clinical Oncology and Archives of Pathology and Laboratory Medicine and was one of authors of ASCO/CAP Guidelines for ER/PR published in Journal of Clinical Oncology and Archives of Pathology and Laboratory Medicine in 2010. He also serves as a Consulting Professor of Pathology Stanford University.
Senior Vice President, Head of Oncology Clinical Development, Millennium: The Takeda Oncology Company
Michael Vasconcelles, M.D., joined Millennium: The Takeda Oncology Company in 2012 as Senior Vice President, Head of Clinical Development. As part of Millennium's Medical Division Management and Administration, Dr. Vasconcelles has assumed responsibility for the clinical development strategy and execution of the oncology portfolio.
Prior to 2012, Dr. Vasconcelles served as Global Therapeutic Area Head, Transplant and Oncology, at Genzyme. He was responsible for the clinical development and product support of Genzyme's hematologic transplant and oncology portfolio. As a member of the Transplant and Oncology Management team, and Chair of the Transplant and Oncology R&D Council, Dr. Vasconcelles also provided strategic support and oversight to oncology research, business development and commercial strategy for the business. In 2011, following the acquisition of Genzyme by Sanofi, he led the realignment of Genzyme Oncology R&D with Sanofi Global Oncology and was named the Head, Personalized Medicine and Companion Diagnostics.
Before he joined Genzyme, Dr. Vasconcelles was a full time associate physician at Brigham and Women's Hospital and Dana-Farber Cancer Institute. He remains an associate physician at both institutions. He has been on the faculty of the Harvard Medical School since 1996, where he is currently a clinical instructor of medicine.
Dr. Vasconcelles recieved both his B.A. and his M.D. from Northwestern University.
Senior Vice President, Medical, Science and Innovation, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Senior Vice President, Medical, Science and Innovation for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth leads all new test development efforts and is responsible for all science and innovation throughout the company. He also is responsible for Medical Affairs and has a functional reporting responsibility for Medical Quality.
Dr. Wohlgemuth has many years of experience in diagnostics and research and development. Prior to joining Quest Diagnostics in 2009, Dr. Wohlgemuth was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab for Genentech. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. Dr. Wohlgemuth also served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos.
Dr. Wohlgemuth serves as a board member of the Personalized Medicine Coalition, an organization devoted to educating about personalized medicine and promoting new ways of thinking about healthcare. Dr. Wohlgemuth earned his bachelor’s degree in biology from Harvard College and his medical degree from Stanford University School of Medicine, where he also served a fellowship in cardiovascular medicine.